Clinical efficacy of caspofungin in the treatment of invasive aspergillosis

References

• Steinbach WJ, Steven DA, Denning DW, Moss RB. Advances against aspergillosis. Clin Infect Dis 2003; 37(Suppl. 3)S155–S156
   Google Scholar
• McNeil MM, Nash SL, Hajjeh RA, et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980–1997. Clin Infect Dis 2001; 33: 641–647
   PubMed Web of Science ®Google Scholar
• Angelbeck JH. Nosocomial aspergillosis – the risk at the water tap of shower. ClinUpAspergillus. Pall Medical 2004; 3–9.
   PubMed Web of Science ®Google Scholar
• Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100: 4358–4366
   PubMed Web of Science ®Google Scholar
• Parquin F. Prévention du risque aspergillaire chez les patients immunodéprimés. Conférence de Consensus, Institut Pasteur –. ParisFrance, 2000.
   Google Scholar
• Herbrecht R, Denning DW, Patterson TF. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408–415
   PubMed Web of Science ®Google Scholar
• Cornely OA, Maertens J, Bresnik M, Herbrecht R. Liposomal amphotericin B (L-AmB) as initial therapy for invasive filmentous fungal infections (IFFI): a randomised, prospective trial of a high loading regimen vs standard dosing (Ambiload trial). Amercian Society of Heamatology, AtlantaUSA, December, 2005.
   Google Scholar
• Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39: 1563–1571
   PubMed Web of Science ®Google Scholar
• Kartsonis NA, Saah AJ, Joy Lipka C, et al. Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study. J Infect 2005; 50: 196–205
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998; 26: 1383–1396
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Goodman JL, Pappas P, et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother 2001; 45: 3487–3496
   PubMed Web of Science ®Google Scholar
• White MH., Anaissie EJ, Kusne S, et al. Amphotericin B colloidal dispersion vs. Amphotericin B as therapy for invasive aspergillosis. Clin Infect Dis 1997; 24: 635–642
   PubMed Web of Science ®Google Scholar
• Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34: 563–571
   PubMed Web of Science ®Google Scholar
• Denning DW, Lee JY, Hostetler JS, et al. NIAID mycoses study group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med 1994; 97: 135–144. Erratum in: Am J Med
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Sable C, De Pauw B, et al. A randomized, double-blind, multicenter trial of caspofungin vs liposomal amphotericin B for empirical antifungal therapy of persistently febrile neutropenic patients. N Eng J Med 2004; 351: 1391–1403
   PubMed Web of Science ®Google Scholar
• Candoni A, Mestroni R, Damiani D, et al. Caspofungin as first line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies. Eur J Haematol 2005; 75: 227–233
   PubMed Web of Science ®Google Scholar
• Mukherjee P, Sheehan DJ, Hitchcock CA. Combination treatment of invasive fungal infections. Clin Microbiol Rev 2005; 18: 163–194
   PubMed Web of Science ®Google Scholar
• Kirkpatrick WR, Perea S, Coco BJ, Patterson TF. Efficacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother 2002; 46: 2564–2568
   PubMed Web of Science ®Google Scholar
• Aliff TB, Maslak PG, Jurcic JG, et al. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer 2003; 97: 1025–1032
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Hachem R, Lewis RE, et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 2003; 98: 292–299
   PubMed Web of Science ®Google Scholar
• Nivoix Y, Zamfir A, Lutun P, et al. Combination of caspofungin and an azole or an amphotericin B formulation in invasive fungal infections. J Infect 2006; 52: 67–74
   PubMed Web of Science ®Google Scholar
• Marr KA, Boechk M, Carter RA, Kim HW, Cory L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004; 39: 797–802
   PubMed Web of Science ®Google Scholar
• Maertens J, Glasmacher A, Herbrecht R , et al Multicenter, noncomparative study of caspofungin combined with other antifungals in adults with invasive aspergillosis (IA) refractory or intolerant to prior therapy: final data. 45th ICAAC, Washington, December, 2005.
   Google Scholar
• Marr KA, Hachem R, Papanicolaou, et al. Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A. Transplant Infec Dis 2004; 6: 110–116
   PubMedGoogle Scholar
• Sanz-Rodriguez C, Lopez-Duarte M, Jurado M, et al. Safety of the concomitant use of caspofungin and cylosporin A in patients with invasive fungal infections. Bone Marrow Transplant 2004; 34: 13–20
   PubMed Web of Science ®Google Scholar